Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2020
Reporting Period: Event date January 7, 2020
The filing reports an unregistered sale of equity securities pursuant to Item 3.02. The Company exercised a right under a letter agreement dated December 23, 2019, to require an investor to purchase additional shares.
Key Financial Metrics
This filing does not contain comprehensive financial statements (revenue, profit, cash flow, or margins). It reports a specific capital raise transaction:
- Capital Raised: $2.0 million
- Shares Issued: 1,250,000 shares of Class A common stock
- Price Per Share: $1.60
- Investor: MacAndrews & Forbes Group LLC
Debt, liquidity, and operating margin data are not provided in this document.
Material Changes
The material change reported is the increase in outstanding Class A common stock and the infusion of $2.0 million in cash from the Investor. This transaction was executed following the signing of definitive documentation between the Company and the Investor.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the transaction details are qualified by reference to the December 2019 Letter Agreement. No unusual items or contingencies are described in the text provided.
Investor Verification Checklist
- Verify the full terms of the December 23, 2019 Letter Agreement (to be filed as an exhibit to the 2019 Form 10-K).
- Confirm the total number of outstanding shares post-transaction to assess dilution impact.
- Review the Company's cash position in the most recent 10-Q or 10-K to understand the liquidity impact of the $2.0 million raise.
- Check for any subsequent filings regarding the use of proceeds from this capital raise.